Homeodomain-interacting Protein Kinase 1 (HIPK1) Expression in Breast Cancer Tissues

Byeongwoo Park, Seho Park, JaSeung Koo, Seung Il Kim, Ji Min Park, Jung Hoon Cho, Hyung Seok Park

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: This study investigated the incidence and clinical significance of homeodomain-interacting protein kinase 1 expression in breast cancer patients. Methods: We investigated immunohistochemical homeodomain-interacting protein kinase 1 expression from tissue microarrays of 1032 patients. The association of homeodomain-interacting protein kinase 1 expression pattern, clinicopathologic factors and survival outcome was evaluated. Tumors with ≥10% stained cells were considered positive for homeodomain-interacting protein kinase 1. Results: Non-cancerous breast tissue, pTis and pT1mic lesions did not show homeodomain-interacting protein kinase 1 expression at any sites. Of the 859 invasive tumors, 124 (14.4%) showed homeodomain-interacting protein kinase 1 expression with three different expression patterns: cytoplasmic (2.4%), nuclear (6.3%), and both cytoplasmic and nuclear (5.7%). Cytoplasmic homeodomain-interacting protein kinase 1-positive tumors showed distinctive features such as fewer nodal metastases, but were frequently Grade III, estrogen receptor-negative, progesterone receptor-negative, HER2-positive, highly proliferative and molecular apocrine tumors. No significant difference in clinicopathologic features was identified between negative and nuclear homeodomain-interacting protein kinase 1-positive tumors. Both cytoplasmic and nuclear HIPK1-positive tumors represent frequent small size, node negativity and moderately differentiated features. Survival was not significantly different by homeodomain-interacting protein kinase 1 expression patterns. Conclusions: Homeodomain-interacting protein kinase 1 expression was identified only in invasive breast cancer cells with three different patterns: cytoplasmic, nuclear, and both cytoplasmic and nuclear. Although the mechanism is not certain, the subcellular localization of HIPK1 expression is associated with tumor histopathologic characteristics and different functions.

Original languageEnglish
Article numberhys163
Pages (from-to)1138-1145
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume42
Issue number12
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Homeodomain Proteins
Protein Kinases
Breast Neoplasms
Neoplasms
Nuclear Proteins
Survival
Progesterone Receptors
Estrogen Receptors
Breast
Cohort Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Park, Byeongwoo ; Park, Seho ; Koo, JaSeung ; Kim, Seung Il ; Park, Ji Min ; Cho, Jung Hoon ; Park, Hyung Seok. / Homeodomain-interacting Protein Kinase 1 (HIPK1) Expression in Breast Cancer Tissues. In: Japanese Journal of Clinical Oncology. 2012 ; Vol. 42, No. 12. pp. 1138-1145.
@article{39152348251f4092a370c90ef898a3d9,
title = "Homeodomain-interacting Protein Kinase 1 (HIPK1) Expression in Breast Cancer Tissues",
abstract = "Objective: This study investigated the incidence and clinical significance of homeodomain-interacting protein kinase 1 expression in breast cancer patients. Methods: We investigated immunohistochemical homeodomain-interacting protein kinase 1 expression from tissue microarrays of 1032 patients. The association of homeodomain-interacting protein kinase 1 expression pattern, clinicopathologic factors and survival outcome was evaluated. Tumors with ≥10{\%} stained cells were considered positive for homeodomain-interacting protein kinase 1. Results: Non-cancerous breast tissue, pTis and pT1mic lesions did not show homeodomain-interacting protein kinase 1 expression at any sites. Of the 859 invasive tumors, 124 (14.4{\%}) showed homeodomain-interacting protein kinase 1 expression with three different expression patterns: cytoplasmic (2.4{\%}), nuclear (6.3{\%}), and both cytoplasmic and nuclear (5.7{\%}). Cytoplasmic homeodomain-interacting protein kinase 1-positive tumors showed distinctive features such as fewer nodal metastases, but were frequently Grade III, estrogen receptor-negative, progesterone receptor-negative, HER2-positive, highly proliferative and molecular apocrine tumors. No significant difference in clinicopathologic features was identified between negative and nuclear homeodomain-interacting protein kinase 1-positive tumors. Both cytoplasmic and nuclear HIPK1-positive tumors represent frequent small size, node negativity and moderately differentiated features. Survival was not significantly different by homeodomain-interacting protein kinase 1 expression patterns. Conclusions: Homeodomain-interacting protein kinase 1 expression was identified only in invasive breast cancer cells with three different patterns: cytoplasmic, nuclear, and both cytoplasmic and nuclear. Although the mechanism is not certain, the subcellular localization of HIPK1 expression is associated with tumor histopathologic characteristics and different functions.",
author = "Byeongwoo Park and Seho Park and JaSeung Koo and Kim, {Seung Il} and Park, {Ji Min} and Cho, {Jung Hoon} and Park, {Hyung Seok}",
year = "2012",
month = "12",
day = "1",
doi = "10.1093/jjco/hys163",
language = "English",
volume = "42",
pages = "1138--1145",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "12",

}

Homeodomain-interacting Protein Kinase 1 (HIPK1) Expression in Breast Cancer Tissues. / Park, Byeongwoo; Park, Seho; Koo, JaSeung; Kim, Seung Il; Park, Ji Min; Cho, Jung Hoon; Park, Hyung Seok.

In: Japanese Journal of Clinical Oncology, Vol. 42, No. 12, hys163, 01.12.2012, p. 1138-1145.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Homeodomain-interacting Protein Kinase 1 (HIPK1) Expression in Breast Cancer Tissues

AU - Park, Byeongwoo

AU - Park, Seho

AU - Koo, JaSeung

AU - Kim, Seung Il

AU - Park, Ji Min

AU - Cho, Jung Hoon

AU - Park, Hyung Seok

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Objective: This study investigated the incidence and clinical significance of homeodomain-interacting protein kinase 1 expression in breast cancer patients. Methods: We investigated immunohistochemical homeodomain-interacting protein kinase 1 expression from tissue microarrays of 1032 patients. The association of homeodomain-interacting protein kinase 1 expression pattern, clinicopathologic factors and survival outcome was evaluated. Tumors with ≥10% stained cells were considered positive for homeodomain-interacting protein kinase 1. Results: Non-cancerous breast tissue, pTis and pT1mic lesions did not show homeodomain-interacting protein kinase 1 expression at any sites. Of the 859 invasive tumors, 124 (14.4%) showed homeodomain-interacting protein kinase 1 expression with three different expression patterns: cytoplasmic (2.4%), nuclear (6.3%), and both cytoplasmic and nuclear (5.7%). Cytoplasmic homeodomain-interacting protein kinase 1-positive tumors showed distinctive features such as fewer nodal metastases, but were frequently Grade III, estrogen receptor-negative, progesterone receptor-negative, HER2-positive, highly proliferative and molecular apocrine tumors. No significant difference in clinicopathologic features was identified between negative and nuclear homeodomain-interacting protein kinase 1-positive tumors. Both cytoplasmic and nuclear HIPK1-positive tumors represent frequent small size, node negativity and moderately differentiated features. Survival was not significantly different by homeodomain-interacting protein kinase 1 expression patterns. Conclusions: Homeodomain-interacting protein kinase 1 expression was identified only in invasive breast cancer cells with three different patterns: cytoplasmic, nuclear, and both cytoplasmic and nuclear. Although the mechanism is not certain, the subcellular localization of HIPK1 expression is associated with tumor histopathologic characteristics and different functions.

AB - Objective: This study investigated the incidence and clinical significance of homeodomain-interacting protein kinase 1 expression in breast cancer patients. Methods: We investigated immunohistochemical homeodomain-interacting protein kinase 1 expression from tissue microarrays of 1032 patients. The association of homeodomain-interacting protein kinase 1 expression pattern, clinicopathologic factors and survival outcome was evaluated. Tumors with ≥10% stained cells were considered positive for homeodomain-interacting protein kinase 1. Results: Non-cancerous breast tissue, pTis and pT1mic lesions did not show homeodomain-interacting protein kinase 1 expression at any sites. Of the 859 invasive tumors, 124 (14.4%) showed homeodomain-interacting protein kinase 1 expression with three different expression patterns: cytoplasmic (2.4%), nuclear (6.3%), and both cytoplasmic and nuclear (5.7%). Cytoplasmic homeodomain-interacting protein kinase 1-positive tumors showed distinctive features such as fewer nodal metastases, but were frequently Grade III, estrogen receptor-negative, progesterone receptor-negative, HER2-positive, highly proliferative and molecular apocrine tumors. No significant difference in clinicopathologic features was identified between negative and nuclear homeodomain-interacting protein kinase 1-positive tumors. Both cytoplasmic and nuclear HIPK1-positive tumors represent frequent small size, node negativity and moderately differentiated features. Survival was not significantly different by homeodomain-interacting protein kinase 1 expression patterns. Conclusions: Homeodomain-interacting protein kinase 1 expression was identified only in invasive breast cancer cells with three different patterns: cytoplasmic, nuclear, and both cytoplasmic and nuclear. Although the mechanism is not certain, the subcellular localization of HIPK1 expression is associated with tumor histopathologic characteristics and different functions.

UR - http://www.scopus.com/inward/record.url?scp=84870441683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870441683&partnerID=8YFLogxK

U2 - 10.1093/jjco/hys163

DO - 10.1093/jjco/hys163

M3 - Article

C2 - 23071292

AN - SCOPUS:84870441683

VL - 42

SP - 1138

EP - 1145

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 12

M1 - hys163

ER -